AMA seeks tighter control of prescribing information in the US

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.294, 2001-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Changes to US Lovenox prescribing information

By  

Inpharma, Vol. 1, Iss. 1452, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Prescribing information revised for cerivastatin in the US and UK

By  

Inpharma, Vol. 1, Iss. 1295, 2001-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Isotretinoin prescribing on the increase in the US

By  

Inpharma, Vol. 1, Iss. 1340, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Currently, the US FDA is not requiring changes to the prescribing information of Tysabri [natalizumab] or to the risk management plan

By  

Reactions Weekly, Vol. 1, Iss. 1271, 2009-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Olmesartan medoxomil achieves tighter BP control than amlodipine

By  

Inpharma, Vol. 1, Iss. 1395, 2003-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite